Stock search

Ticker or company name

Vertex Pharmaceuticals

VRTX · NASDAQ · Biotechnology

$537,79Down −0,81 (−0,15%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$142 bn
Div. yield
—
Year to date
+18,8%
52 weeks: $412,27$568,67

Ratio score

72/100
Ratio would consider buying

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

5 ✓ · 3 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM33,726,242,1
Forward P/E27,2—18,7
PEG3,0—4,1
P/S10,39,56,6
EV/EBITDA29,619,628,2
P/FCF41,9—26,0
P/B6,46,09,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 39 analysts

Buy
32
Hold
6
Sell
1

Beat the EPS forecast in 1 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20264,884,76Down −2,5%
Q2 20264,834,73Down −2,1%
Q1 20264,404,47Up +1,6%
Q4 20255,175,03Down −2,8%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue3,44 bn3,33 bn2,99 bn3,19 bn3,08 bn2,96 bn2,77 bn2,91 bn2,77 bn2,65 bn2,69 bn2,52 bn
EPS2,564,314,024,644,203,992,493,534,01−13,924,213,71
Margin19,0%33,0%34,5%37,3%35,2%34,8%23,3%31,4%37,7%−135,8%40,9%38,5%
FCF546 m1,01 bn1,29 bn349 m1,14 bn927 m778 m492 m1,30 bn−3,82 bn1,24 bn177 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $130 m.

NameAmountSharesPrice
kewalramani reshma6 Nov 2026 · sale$6,31 m11 866$531,53
mckechnie duncan2 Jul 2026 · sale$799 7791 541$519,00
tatsis ourania2 Jul 2026 · sale$787 4851 500$524,99
liu joy1 Jul 2026 · sale$416 244828$502,71
bozic carmen18 Jun 2026 · sale$471 4131 020$462,17
bozic carmen5 Jun 2026 · sale$785 2501 745$450,00
liu joy1 Jun 2026 · sale$364 245828$439,91
bozic carmen29 May 2026 · sale$888 3001 974$450,00
bunnage mark e.15 May 2026 · sale$14 96433$453,45
bozic carmen15 May 2026 · sale$613 9711 354$453,45
bozic carmen12 May 2026 · sale$3,14 m6 988$450,00
bhatia sangeeta n.4 May 2026 · sale$134 746318$423,73
liu joy1 May 2026 · sale$469 2221 104$425,02
liu joy1 Apr 2026 · sale$439 288978$449,17
bozic carmen27 Mar 2026 · sale$1,05 m2 329$450,95

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
24 Jul 1991

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
MRNAModerna$215,2722would not consider—+13,1%−110,5%
AMGNAmgen$462,3267would watch26,8+8,2%24,1%
ABBVAbbVie$294,5572would consider50,4+10,7%15,7%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.